Skip to main content
. 2020 Aug 27;43(11):2873–2877. doi: 10.2337/dc20-1016

Table 1.

Demographics and results

UC RT-CGM
(n = 53) (n = 57) P value
Baseline demographicsa
 Age, mean (SD) 60.94 (12.37) 62.88 (14.01) 0.5946
 Male, n (%) 23 (43.4) 27 (47.4) 0.6759
 Hispanic, n (%) 42 (80.8) 39 (68.4) 0.5620
 T2D duration, years, mean (SD) 18.51 (12.04) 16.23 (9.74) 0.5653
Clinical characteristics at admissiona
 HbA1c, % 8.65 (7.68–10.53) 9.5 (7.6–11.1) 0.7957
 POC, mg/dL 245.5 (196.5–298.25) 261 (213–315) 0.7957
 Serum creatinine, mg/dL 1.00 (0.70–1.90) 1.00 (0.60–2.10) 0.7956
 Hematocrit, %, mean (SD) 36.42 (6.08) 36.11 (7.02) 0.8012
 eGFR, mL/min/1.73 m2, n (%) 0.8012
  <30 15 (28.3) 17 (29.8)
  30–45 6 (11.3) 5 (8.8)
  46–60 3 (5.7) 1 (1.8)
  >60 29 (54.7) 34 (59.7)
 BMI, kg/m2 30.65 (25.27–36.20) 29.9 (25.02–33.40) 0.7957
 Primary admission diagnosis, n (%) 0.3199
  Infection 27 (50.9) 23 (40.4)
  Cardiac 4 (7.6) 11 (19.3)
  Diabetes, glucose-related 6 (11.3) 10 (17.5)
  Pulmonary, noninfection 4 (7.6) 9 (15.8)
  Orthopedic 3 (5.7) 0 (0.0)
  Other 9 (17.0) 4 (7.0)
Hospitalization statistics
 Length of stay, days 5.0 (3.0–9.0) 5.0 (3.0–8.0) 0.9880
 Glucose-affecting medications, n (%)b
  Steroids 14 (26.4) 16 (28.1) 0.9490
  Psychotropics 11 (20.8) 5 (8.8) 0.6545
  Quinolones 6 (11.3) 3 (5.3) 0.8360
  Dextrose-containing fluids 19 (35.9) 24 (42.1) 0.8360
  Other 2 (3.8) 1 (1.8) 0.9490
 Insulin dosing, units/kg/day
  Long-acting 0.25 (0.16–0.34) 0.26 (0.19–0.32) 0.9094
  Rapid-acting 0.31 (0.20–0.40) 0.26 (0.18–0.36) 0.9094
  Total 0.50 (0.31–0.70) 0.53 (0.33–0.64) 0.9094
Glucose outcomesc
 POC, mg/dL, mean (SD) 212.40 (45.91) 191.50 (38.89) 0.0115
 CGM
  CGM duration, in h 47.75 (25.92–80.42) 51.00 (25.33–96.25) 0.8091
  Mean glucose, mg/dL, mean (SD) 238.05 (45.26) 219.51 (43.75) 0.0311
  SD glucose, mg/dL, mean (SD) 57.16 (19.44) 54.58 (16.94) 0.7041
  CV glucose, mg/dL, mean (SD) 24.78 (9.20) 25.41 (8.07) 0.7041
  % TIR
   70–180 mg/dL 19.89 (3.34–40.09) 25.31 (11.78–42.97) 0.1460
   70–200 mg/dL 33.38 (10.90–55.74) 42.82 (25.66–58.53) 0.0615
   70–250 mg/dL 63.95 (31.25–77.95) 72.83 (59.03–83.57) 0.0404
  % Hyperglycemia
   >250 mg/dL 32.96 (20.40–68.75) 27.00 (16.01–40.97) 0.0403
   >300 mg/dL 13.10 (2.90–39.40) 7.33 (2.03–18.54) 0.0512
  % Hypoglycemia
   <70 mg/dL 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.2680
   <54 mg/dL 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.8093
  Hypoglycemic eventsd
   N (%) with ≥1 event(s)
       <70 mg/dL 5 (9.43) 11 (19.3)
       <54 mg/dL 2 (3.77) 4 (7.02)
  Number of eventse
      <70 mg/dL 2.00 (1.00–4.00) 1.00 (1.00–1.50)
      <54 mg/dL 3.50 (2.75–4.25) 1.00 (1.00–2.25)
  Duration of eventse
      <70 mg/dL
       Number of readings 19.00 (15.00–20.25) 9.00 (7.50–11.00)
       Time, in min 95.00 (75.00–101.25) 45.00 (37.50–55.00)
      <54 mg/dL
       Number of readings 9.40 (7.20–11.60) 7.92 (7.38–12)
       Time, in min 47.00 (36.00–58.00) 39.59 (36.88–60)

Data are median (interquartile range) unless otherwise specified. All reported P values are two-sided. Multiple comparisons within outcomes were accounted for using the false-discovery rate adjustment. CV, coefficient of variation.

aAs a result of missing data at admission, the following represent the sample sizes for each: Hispanic (n = 52, 57), T2D duration (n = 51, 56), HbA1c (n = 44, 49), POC (n = 52, 55), and BMI (n = 48, 56), in UC and RT-CGM, respectively. bStatistics reflect the n (%) of participants who were administered the glucose-affecting medication at any time during the hospitalization. cReported P values are derived from unadjusted linear regression models for each outcome with group as a fixed effect, except for both % hypoglycemia measures, which were derived from Mann-Whitney U tests due to skewed distribution. dDefined as four or more consecutive values below respective threshold. eAs a result of the low frequency of events in the overall sample, data are presented for participants with one or more hypoglycemic event. P values are not presented due to small n in these subanalyses.